Late Breaker

 General hepatology

Main Plenary
English
Science/Research
13 April 2019 16:00 - 18:00


Presentations

LB-01 Multicenter, double-blind, placebo-controlled, randomized trial of emricasan in subjects with NASH cirrhosis and severe portal hypertension
Guadalupe Garcia-Tsao - United States
13 April 2019 16:00 - 16:15

Abstract
LB-02 Elafibranor, a peroxisome proliferator-activted receptor alpha and delta agonist demonstrates favourable efficacy and safety in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid treatment
VELIMIR LUKETIC - United States
13 April 2019 16:15 - 16:30

Abstract
LB-03 Tenofovir treatment has lower risk of hepatocellular carcinoma than entecavir treatment in patients with chronic hepatitis B
Terry Cheuk-Fung Yip - Hong Kong
13 April 2019 16:30 - 16:45

Abstract
LB-04 Efficacy and safety of sofosbuvir monotherapy in patients with chronic hepatitis E – The HepNet SofE pilot study
Markus Cornberg - Germany
13 April 2019 16:45 - 17:00

Abstract
LB-05 Bezafibrate improves the effect of obeticholic acid on cholestasis in patients with primary biliary cholangitis
Lena Smets - Belgium
13 April 2019 17:00 - 17:15

Abstract
LB-06 Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients
Jacob Lalezari - United States
13 April 2019 17:15 - 17:30

Abstract
LB-07 Effectiveness of therapy in 16,567 directly-acting antiviral treated people in England: High response rates in genotype 3 hepatitis C infection regardless of degree of fibrosis, but ribavirin improves response in cirrhosis
Kate Drysdale - United Kingdom
13 April 2019 17:30 - 17:45

Abstract
LB-08 Growth analysis in children with progressive familial intrahepatic cholestasis treated with the apical sodium-dependent bile acid transporter inhibitor maralixibat
Alexander Miethke - United States
13 April 2019 17:45 - 18:00

Abstract